Targeted immunotherapy has revolutionized cancer therapy, but its use remains limited in the solid tumor setting.
Thelper has discovered novel viral targets highly expressed within the tumor and its microenvironment, but absent in normal, healthy tissue. We are actively leveraging our discovery to create highly potent, first-in-class immunotherapies against these tumor-associated viral antigens.
We are a company that aims to TRANSFORM the treatment paradigm for solid tumor patients, and positively IMPACT their life.
Thelper has licensed a humanized, silenced Fc variant from mAbsolve Inc. that is engineered into all our therapeutic candidates. This novel Fc variant is comprehensively more silenced than all previous attempts (including LALA, LALAPG, aglycosylated, etc), completely abolishing FcR binding, C1q activation, and cytokine release from PBMCs. However, binding to FcRn is preserved, allowing the increased half life not seen in other BiTE or nanobody variants. This fully silenced Fc variant will further reinforce the safety profile of Thelper´s therapeutic candidates by eliminating undesirable FcR effector activity in patients.
Thelper has partnered with Selexis SA to develop cell lines that will produce Thelper's first-in-class, antiviral candidate antibodies and bispecifics. With its SUREtechnology Platform™, which combines sophisticated genetic engineering techniques and advanced screening methodologies, the rapid generation and selection of highly productive, optimized cell lines will enable efficient and scalable production of Thelper's therapeutic antibodies.